Off-Label Ixekizumab is Effective for HS After Treatment Failure with Adalimumab
Peter Lio, MD, Advocates for Personalized Pediatric Dermatology
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Top 5 Articles of the Week: April 27-May 2